South Korea · Delayed Price · Currency is KRW AptaBio Therapeutics Company Description
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases.
Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs.
The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells.
The company was founded in 2009 and is based in Yongin-si, South Korea.
| Country | South Korea |
| Founded | 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Jin Soo |
Contact Details
Address: Heungdeok IT Valley, 13 Yongin-si, 16954 South Korea | |
| Phone | 82 3 1365 3693 |
| Website | aptabio.com |
Stock Details
| Ticker Symbol | 293780 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7293780003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jin Soo | Chief Executive Officer |